Navigation Links
CMC Contrast Granted Orphan Drug Designation by the FDA for its Liver Specific MRI Contrast Media CMC-001

LUND, Sweden, November 27, 2013 /PRNewswire/ --

CMC Contrast AB, a privately owned drug development company that is developing a targeted contrast agent for Magnetic Resonance Imaging (MRI), announced today that Orphan Drug Designation has been granted by the US Food and Drug Administration (FDA) for its liver specific contrast agent CMC-001. The Orphan Drug Designation has been granted for CMC-001 for use as a targeted contrast agent for diagnostic MRI for detection and localization of focal liver lesions in patients where gadolinium-based contrast agents are contraindicated or cannot be administered.

Orphan Drug Designation is granted by the FDA Office of Orphan Drug Products to novel drugs intended to treat a rare disease or condition affecting fewer than 200,000 people in the U.S. The designation confers special incentives to the drug developer, including tax credits towards the cost of clinical trials, prescription drug user fee waivers and may entitle a period of seven years U.S market exclusivity upon FDA approval.

Magnus Corfitzen, Chairman of CMC Contrast AB "The diagnostic benefits of enhanced MRI liver imaging in detecting and localizing focal liver lesions are well established. However, a small subset of patient groups cannot undergo enhanced liver MRI procedures due to the risks of severe side effects associated with currently used gadolinium based contrast agents. For these patients, including patients with severe chronic renal insufficiency, important diagnostic information may be missed due to lack of contrast enhanced MRI. CMC-001 will allow radiologists to obtain the best possible diagnostic information in these subsets of patients, enabling clinicians to select the optimal treatment option for these patients. This is not possible today as clinicians only have access to data from an unenhanced imaging procedure on which they will base their disease management decisions for these patients"

The FDA decision to grant the Orphan Drug Designation to CMC-001 is an important milestone for CMC Contrast AB.  The company is now planning a pivotal phase III clinical program which in conjunction with the completed phase I and II clinical studies should enable CMC-001 to obtain regulatory approval and marketing authorization in the US. CMC-001 will then become available to patients in need of a liver MRI procedure for whom gadolinium based contrast agents are contraindicated or cannot be administered.

About CMC Contrast

CMC Contrast AB is a privately owned drug development company that specializes in developing targeted contrast agents for Magnetic Resonance Imaging (MRI). CMC Contrast AB's product CMC-001 is the world's first oral contrast agent for MRI of the liver. CMC-001 is an oral manganese-based contrast agent which enables safe liver enhancement in MRI, in patients for whom gadolinium based contrast agents are contraindicated or cannot be administered. A liver MRI scan is a specialized radiology procedure used to examine the liver to identify certain conditions or diseases which can be malignant cancerous or benign lesions.

CMC Contrast is based in Lund, Sweden, and funded by prominent VC investors including Sunstone Capital, Industrifonden and Øresund Healthcare.

Magnus Corfitzen
Chairman, CMC Contrast AB
Tel: +45-40-80-48-63

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Imaging Markets: Contrast Agents
2. Radiopharmaceuticals and Contrast Media: Frost & Sullivan Predicts Market Growth in Europe
3. Diagnostic Imaging Covers Communicating Contrast Agent Risk
4. Contrasting Reimbursement Environments Result in Different Prescribing Patterns for Premium-Priced Therapies in China and South Korea
5. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
6. Broad Patent Protection Granted for iBio Immunomodulator
7. BiO2 Medical Granted CE Mark for the Angel™ Catheter, the First IVC Filter with a Prophylactic Use Indication
8. QRxPharma Granted Additional US Patent on MoxDuo®
9. Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
10. Unilife Granted Key U.S. Patent for Unifill Prefilled Syringe
11. Vomaris patent estate grows to six issued U.S. patents and three granted international patents with U.S. Pat. No. 8,224,439
Post Your Comments:
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
Breaking Medicine News(10 mins):